Theravance has submitted a New Drug Application to the FDA for telavancin, its drug candidate for hospital-acquired pneumonia caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus. "The submission of the telavancin NDA for HAP is another important milestone for the telavancin program," CEO Rick Winningham said.

Full Story:
RTT News

Related Summaries